Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00080743 · ClinicalTrials.gov registry record · Phase 2

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
Phase 2
Development phase
2
Enrollment target
1
Study location

NCT00080743: Completed Phase 2 study of Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.

NCT00080743 is a Phase 2 study of Breast Cancer that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 2 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00080743, a Phase 2 study of Breast Cancer, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Combining gefitinib with tamoxifen may be effective in killing tumor cells that have become resistant (stopped responding) to tamoxifen. PURPOSE: This randomized phase II trial is studying how well giving gefitinib together with tamoxifen works compared to gefitinib alone in treating patients with metastatic breast cancer that has stopped responding to tamoxifen.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Placebo
  • DRUG gefitinib
  • DRUG tamoxifen citrate

Study Locations (1)

New Hampshire

  • Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2004-01
Est. Completion 2005-11
Phase Phase 2
Dartmouth-Hitchcock Medical Center

427 total trials

What the finished NCT00080743 record still lists

NCT00080743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00080743 reports a single indexed study location in New Hampshire.

Frequently Asked Questions

What is clinical trial NCT00080743 about?

NCT00080743 is a clinical study titled "Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer". RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Combining gefitinib with tamoxifen may be effective in killing tumor cells that have...

What is the current status of trial NCT00080743?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2004-01. Estimated completion is 2005-11.

What conditions does trial NCT00080743 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00080743?

The interventions under investigation include: Placebo (DRUG), gefitinib (DRUG), tamoxifen citrate (DRUG).

Who is sponsoring clinical trial NCT00080743?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00080743 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00080743's enrollment target sits among peer trials

2 1220th of 1224 higher than 3 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00080743, the US trial registry maintained by the National Library of Medicine. NCT00080743 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.